Ironwood Pharmaceuticals, Inc. (IRWD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 390 | 414 | 411 | 443 | 351 | 296 | 389 | 467 |
| Operating profit | $m | 119 | 236 | ||||||
| Net profit | $m | 106 | 528 | 175 | -1,002 | 1 | 24 | 130 | 216 |
| EPS reported | $ | 0.15 | 0.77 | ||||||
| Operating cashflow per share | $ | 0.78 | 1.12 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | 0.78 | 1.12 | ||||||
| Free cash flow | $m | 127 | 186 | ||||||
| Net debt | $m | 369 | 306 | ||||||
| Book value equity | $m | -262 | -162 | ||||||
| Book value per share | $ | -1.47 | -0.98 | ||||||
| Number of shares | m | 177.76 | 165.45 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 22.47 | 5.37 | ||||||
| P/B LTM | x | -2.09 | -3.38 | ||||||
| P/S LTM | x | 1.85 | 1.40 | ||||||
| P/FCF LTM | x | 4.30 | 2.95 | ||||||
| EV/EBITDA LTM | x | 8.88 | 3.85 | ||||||
| EV/Sales LTM | x | 3.14 | 2.64 | ||||||
| Earnings Yield LTM | % | +4.45% | +18.62% | ||||||
| FCF Yield | % | +23.23% | +33.94% | ||||||
| Quality | |||||||||
| ROE | % | -9.17% | -57.40% | ||||||
| ROIC | % | +11.39% | +57.85% | ||||||
| Operating margin | % | +40.10% | +60.64% | ||||||
| Gross margin | % | +100.00% | +99.76% | ||||||
| FCF/Sales | % | +42.89% | +47.66% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +2627.3% | - | ||||||
| Sales Growth YoY | % | -15.72% | +10.79% | ||||||
| Net Income Growth YoY | % | +2629.2% | - | ||||||
| FCF Growth | % | +22.83% | +79.44% | ||||||
| Operating Profit Growth | % | +27.53% | +153.51% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.21 | 0.47 | ||||||
| Net Debt/EBITDA | x | 3.65 | 1.32 | ||||||
| EBIT/Net interest | x | 3.63 | 7.23 | ||||||
| Net debt/market cap | % | +1.07% | +54.26% | ||||||
| Net debt/Equity | x | -1.41 | -1.89 | ||||||
| Gross debt/equity | x | -2.28 | -2.45 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
Similar companies
- Fuan Pharmaceutical (Group) Co., Ltd.
- Hunan Hansen Pharmaceutical Co., Ltd.
- Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret A.S.
- Hunan Fangsheng Pharmaceutical Co., Ltd.
- Morepen Laboratories Limited
- Henan Taloph Pharmaceutical Stock Co.,Ltd
- Zhejiang AngLiKang Pharmaceutical CO.,LTD.
- Sun Pharma Advanced Research Company Limited
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Ironwood Pharmaceuticals, Inc. (IRWD)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
- Fuan Pharmaceutical (Group) Co., Ltd.
- Hunan Hansen Pharmaceutical Co., Ltd.
- Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret A.S.
- Hunan Fangsheng Pharmaceutical Co., Ltd.
- Morepen Laboratories Limited
- Henan Taloph Pharmaceutical Stock Co.,Ltd
- Zhejiang AngLiKang Pharmaceutical CO.,LTD.
- Sun Pharma Advanced Research Company Limited
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free